Rwanda rolls out Marburg vaccine trials amid rising cases
Rwanda began administering Marburg vaccine trials, prioritising frontline workers as part of efforts to prevent the spread of Marburg virus disease (MVD) in the country.
Rwandan Health Minister Sabin Nsanzimana on Sunday told a press conference in the national capital of Kigali that the first round of trial vaccinations targets healthcare workers, emergency responders, and individuals who have had contact with confirmed Marburg cases.
"We have received 700 doses of the vaccine, and we are hopeful that more will arrive soon to continue our efforts in safeguarding the health of our people," Nsanzimana said, emphasising the importance of protecting frontline workers, particularly those at high risk of exposure, reports news agency.
"The Marburg vaccine, produced by the Sabin Vaccine Institute, has already proven effective in countries like Uganda and Kenya," Nsanzimana said, emphasising that it is both safe and trusted.